Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Christopher M. Mahaffey"'
Autor:
David R. Gandara, Hongqiao Zhang, Henry Jay Forman, W. S. Holland, Nichole Mahaffey, Christopher M. Mahaffey, Philip C. Mack
Publikováno v:
Journal of Thoracic Oncology. 7:34-39
IntroductionMultidrug-resistant protein-3 (MRP3), a membrane-bound transporter, facilitates efflux of toxic compounds, including certain chemotherapies, out of cells. Aberrant MRP3 expression has been linked to drug resistance in non-small cell lung
Autor:
Regina F Gandour-Edwards, Ruth Louise Vinall, Clifford G. Tepper, Ralph W deVere White, Ryan R. Davis, Paramita M. Ghosh, Zunping Luo, Christopher M. Mahaffey
Publikováno v:
Hormones and Cancer. 2:224-238
We previously demonstrated that H2 relaxin (RLN2) facilitates castrate-resistant (CR) growth of prostate cancer (CaP) cells through PI3K/Akt/β-catenin-mediated activation of the androgen receptor (AR) pathway. As inhibition of this pathway caused on
Autor:
Philip C. Mack, Henry Jay Forman, Christopher M. Mahaffey, Alessandra Rinna, W. S. Holland, Hongqiao Zhang
Publikováno v:
Free radical biologymedicine. 46(12)
Multidrug Resistant Proteins (MRP) are members of the ATP-binding cassette superfamily that facilitate detoxification by transporting toxic compounds, including chemotherapeutic drugs, out of cells. Chemotherapy, radiation, and other xenobiotic stres
Autor:
W. S. Holland, David R. Gandara, Brandi Pryde, Paul H. Gumerlock, Philip C. Mack, Christopher M. Mahaffey, Angela M. Davies, Jr Primo N. Lara
Publikováno v:
Clinical lung cancer. 8(9)
BACKGROUND Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) given concurrently with chemotherapy in 4 large randomized clinical trials did not improve patient outcomes compared with chemotherapy alone in advanced non–small-
Autor:
Yunpeng Ma, Shiloh M. Martin, Hayes McKnight, Robert T. O'Donnell, Christopher M. Mahaffey, Eric Churchill, Joseph Tuscano
Publikováno v:
Journal of Hematology & Oncology
Martin, Shiloh M; Churchill, Eric; McKnight, Hayes; Mahaffey, Christopher M; Ma, Yunpeng; O'Donnell, Robert T; et al.(2011). The HB22.7 Anti-CD22 Monoclonal Antibody Enhances Bortezomib-mediated Lymphomacidal Activity in a Sequence Dependent Manner. Journal of Hematology & Oncology, 4(1), 49. doi: http://dx.doi.org/10.1186/1756-8722-4-49. Retrieved from: http://www.escholarship.org/uc/item/2k29s3d3
Journal of Hematology & Oncology, Vol 4, Iss 1, p 49 (2011)
Martin, Shiloh M; Churchill, Eric; McKnight, Hayes; Mahaffey, Christopher M; Ma, Yunpeng; O'Donnell, Robert T; et al.(2011). The HB22.7 Anti-CD22 Monoclonal Antibody Enhances Bortezomib-mediated Lymphomacidal Activity in a Sequence Dependent Manner. Journal of Hematology & Oncology, 4(1), 49. doi: http://dx.doi.org/10.1186/1756-8722-4-49. Retrieved from: http://www.escholarship.org/uc/item/2k29s3d3
Journal of Hematology & Oncology, Vol 4, Iss 1, p 49 (2011)
Most non-Hodgkin's lymphomas (NHL) initially respond to chemotherapy, but relapse is common and treatment is often limited by chemotherapy-related toxicity. Bortezomib, is a highly selective proteasome inhibitor with anti-NHL activity; it is currentl